COMMUNIQUÉS West-GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
19/03/2026
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- [...]
Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
19/03/2026
Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K [...]
Gain Therapeutics to Present at the 38th Annual ROTH Conference
19/03/2026
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Glass House Brands to Host Fourth Quarter and Full Year 2025 Earnings Call on March 24, 2026
19/03/2026
LONG BEACH, Calif. and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
19/03/2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic [...]
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
19/03/2026
Record f ull year 2025 net sales of $ 32.0 , an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
19/03/2026
CRANFORD, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
19/03/2026
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile [...]
Solésence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026
19/03/2026
ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
19/03/2026
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels pour le Quatrième Trimestre et l'Exercice 2025
19/03/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels pour le Quatrième Trimestre et l'Exercice 2025 La commercialisation aux États-Unis a pris un solide départ au cours du premier trimestre [...]
$1M Donation by Lume Deodorant Founder Marks the Largest Single Gift to Fund Lobular Breast Cancer Research
19/03/2026
Boston, MA, USA, March 19, 2026 (GLOBE NEWSWIRE) -- Lobular Breast Cancer Alliance Launches “Match the Million” Challenge to Double Historic Gift This Women's History Month, Lume Deodorant founder and lobular breast [...]
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
19/03/2026
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Established to Drive [...]
Teva Releases Q1 2026 Aide Memoire
19/03/2026
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q 1 202 6 [...]
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
19/03/2026
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan [...]
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
19/03/2026
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial [...]
Curia renforce ses capacités de production à Glasgow et consolide sa plateforme de développement de lignées cellulaires
19/03/2026
ALBANY, New York, 19 mars 2026 (GLOBE NEWSWIRE) -- Curia, acteur majeur de la recherche, du développement et de la fabrication sous contrat (CDMO), annonce ce jour la progression de l’extension de son site de production [...]
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
19/03/2026
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash [...]
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
19/03/2026
Company announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL [...]

Pages